CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
PF-02341066drug
Likely dose
PF-02341066 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01082380
NCT01082380Phase 1Completed
CompareCT.gov

A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-02341066 In Healthy Male Volunteers

Pfizer·interventional·Posted Mar 8, 2010·Updated Feb 29, 2012

In Brief

A Phase 1 clinical trial evaluating PF-02341066 for Healthy Volunteer. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The rationale for this study is to investigate the absorption, metabolism and excretion of \[14C\]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of \[14C\]PF 02341066 in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 8, 2010
Enrollment StartMar 1, 2010
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.3 years ago

Interventions

PF-02341066drug

oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066